Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)
Symptoms, Doctors, Treatments, Advances & More

Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome) Overview

Save information for later
Sign Up

Learn About Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome) Local Doctors?
Elite in Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)
Pediatric Gastroenterology
Elite in Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)
Pediatric Gastroenterology

UCSF Benioff Children's Hospital Oakland

747 52nd St, 
Oakland, CA 
Languages Spoken:
English
Offers Telehealth

Paul Harmatz is a Pediatric Gastroenterologist practicing medicine in Oakland, California. Dr. Harmatz is rated as an Elite provider by MediFind in the treatment of Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome). He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 6 (MPS VI, Maroteaux-Lamy Syndrome), Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), and Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome). Dr. Harmatz is board certified in American Board Of Pediatrics.

Elite in Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)
Medical Genetics
Elite in Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)
Medical Genetics

Nemours Children's Hospital, Delaware

1600 Rockland Road, 
Wilmington, DE 
Experience:
32+ years
Languages Spoken:
English

Dr. Michael B. Bober is a pediatric geneticist and an authority on skeletal dysplasias, brittle bone disease, primordial dwarfism and other genetic disorders of the skeleton. He is a frequent guest lecturer, accomplished author and consultant for numerous television networks, here and abroad. Dr. Bober is rated as an Elite provider by MediFind in the treatment of Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome). He is also highly rated in 70 other conditions, according to our data. His clinical expertise encompasses Microcephalic Osteodysplastic Primordial Dwarfism Type 2 (MOPD2), Microcephalic Osteodysplastic Primordial Dwarfism Type 1 (MOPD1), Achondroplasia, Osteotomy, and Adenoidectomy. Dr. Bober is board certified in American Board Of Medical Genetics And Genomics.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)
Elite in Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)

Nemours Children's Hospital Delaware

1600 Rockland Rd, 
Wilmington, DE 
Languages Spoken:
English

William Mackenzie is an Orthopedics provider practicing medicine in Wilmington, Delaware. Dr. Mackenzie is rated as an Elite provider by MediFind in the treatment of Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome). He is also highly rated in 59 other conditions, according to our data. His clinical expertise encompasses Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome), Brachydactyly Mononen Type, Achondroplasia, Osteotomy, and Spinal Fusion.

What are the latest Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome) Clinical Trials?
Registry of Patients Diagnosed With Lysosomal Storage Diseases

Summary: This is an international prospective and retrospective registry of patients with Lysosomal Storage Diseases (LSDs) to understand the natural history of the disease and the outcomes of fetal therapies, with the overall goal of improving the prenatal management of patients with LSDs.

Match to trials
Find the right clinical trials for you in under a minute
Get started
PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)

Summary: For detailed information, please view our study website: https://pearltrial.ucsf.edu/ The investigators aims to determine the the maternal and fetal safety and feasibility of in utero fetal enzyme replacement therapy in fetuses with Lysosomal Storage Diseases.